Application of PROTACs in Hematological Malignancies--Review / 中国实验血液学杂志
Journal of Experimental Hematology
; (6): 1921-1924, 2023.
Article
in Chinese
| WPRIM (Western Pacific)
| ID: wpr-1010061
Responsible library:
WPRO
ABSTRACT
Proteolysis-targeting chimeras (PROTACs) are heterobifunctional small molecules by utilizing the ubiquitin proteasome system (UPS) to degrade proteins of interest. PROTACs have exhibited unprecedented efficacy and specificity in degrading various oncogenic proteins because of their unique mechanism of action, ability to target "undruggable" and mutant proteins. A series of PROTACs have been developed to degrade multiple key protein targets for the treatment of hematologic malignancy. Notably, PROTACs that target BCL-XL, IRAK4, STAT3 and BTK have entered clinical trials. The known PROTACs that have the potential to be used to treat various hematological malignancies are systematically summarized in this review.
Full text:
Available
Database:
WPRIM (Western Pacific)
Main subject:
Hematologic Neoplasms
/
Ubiquitin-Protein Ligases
/
Proteasome Endopeptidase Complex
/
Proteolysis Targeting Chimera
Limits:
Humans
Language:
Chinese
Journal:
Journal of Experimental Hematology
Year:
2023
Document type:
Article